BofA Securities on Regeneron Pharma (REGN): 'Updating model for 4Q Eylea and other recent disclosures'
Tweet Send to a Friend
BofA Securities analyst Tim Anderson reiterated a Buy rating and $860.00 price target on Regeneron Pharma (NASDAQ: REGN).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
